The Food and Drug Administration has given the green light to Vuity 1.25%, the first approved prescription, once-daily eye drops to treat age-related blurry near vision.

Two years later, 92 percent had good near vision — 20/40 or better without glasses — in the implanted eye. Potential side effects include infection, dry eye, glare and corneal problems ...

USE VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults. IMPORTANT SAFETY INFORMATION ...

The first FDA-approved eye drops to treat age-related blurry near vision (presbyopia) has gone on sale in the US, offering a potential alternative to reading glasses for the estimated 128 million ...

MR-141 met primary endpoint with ≥3-line near vision gain at 12 hours post-dose on Day 8 vs. placebo (p<0.0001). No serious adverse events; most common side effects were mild, including eye ...

One would think that having normal 20/20 vision is due mainly to the anatomical characteristics of the eye. According to a new study, however, tiny eye movements play a large role – and the ...

Share on Pinterest New eye drops approved by federal regulators could help people with age-related blurry vision. Cucurudza/Getty Images Federal regulators approved the use of Vuity, eye drops ...

When the near-vision eye chart was used as the control test, results with the iPad and projected Landolt ring were consistent 76% of the time in the right eye and 83% of the time in the left eye.

Lenz Therapeutics, which is developing daily eye drops to improve near vision for middle-aged folks, has raised $83.5 million in venture capital funding. The round, announced last week, brings the ...